Fundraising Fox

Human Continuum

Jupiter, US · Founded 2025 · Nevada corporation

Human Continuum develops platelet-derived exosome products, including a cell-free biologic, injectable hydrogel-exosome therapies for orthopedic conditions, point-of-care diagnostics, and topical skincare formulations for skin repair and anti-aging. Its offerings target the longevity, orthopedics, dermatology, and med-spa markets.

BiotechLongevityMedical Devices

Founders & leadership

OS
Omar SialExecutive
JY
Jiang YuNamed on SEC filing
TY
Tsun Yee LawNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$3.2M disclosed across 2 rounds · 2026

▶$2.4MraisedJun 2026 · 64 investors · Other
Rule 506(b)
Human Continuum Nets $5 Million-Plus in Seed Round Funding | ODTodtmag.com · Jun 2026Human Continuum Raises $5.13M for Exosome Longevityallsci.com · Jun 2026
Officers, directors & promoters on the filing
  • Jiang YuExecutive Officer, Director
  • Tsun Yee LawExecutive Officer, Director
  • Omar SialExecutive Officer
Offering amount
$2.4M
Amount sold
$2.4M
First sale
May 2026
Incorporated
Corporation, Nevada, 2025
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$722.5KraisedJun 2026 · 12 investors · Other
Rule 506(b)
Human Continuum Nets $5 Million-Plus in Seed Round Funding | ODTodtmag.com · Jun 2026Human Continuum Raises $5.13M for Exosome Longevityallsci.com · Jun 2026
Officers, directors & promoters on the filing
  • Jiang YuExecutive Officer, Director
  • Tsun Yee LawExecutive Officer, Director
  • Omar SialExecutive Officer
Offering amount
$722.5K
Amount sold
$722.5K
First sale
May 2026
Incorporated
Corporation, Nevada, 2025
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Human Continuum Nets $5 Million-Plus in Seed Round Funding | ODTodtmag.com · Jun 2026Human Continuum Raises $5.13M for Exosome Longevityallsci.com · Jun 2026Human Continuum Closes Over $5 Million in Seed Round Funding to Support the Development of its Integrated Exosome-Based Therapeutic Longevity Platformglobenewswire.com · Jun 2026 · press release

Frequently asked questions

What does Human Continuum do?
Human Continuum develops platelet-derived exosome products, including a cell-free biologic, injectable hydrogel-exosome therapies for orthopedic conditions, point-of-care diagnostics, and topical skincare formulations for skin repair and anti-aging. Its offerings target the longevity, orthopedics, dermatology, and med-spa markets.
How much funding has Human Continuum raised?
Human Continuum has disclosed $3.2M raised across 2 rounds.
Where is Human Continuum headquartered?
Human Continuum is headquartered in Jupiter, US.